139 related articles for article (PubMed ID: 35834987)
1. Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer.
Guchelaar NAD; van Eerden RAG; Groenland SL; Doorn LV; Desar IME; Eskens FALM; Steeghs N; van Erp NP; Huitema ADR; Mathijssen RHJ; Koolen SLW;
Biomed Pharmacother; 2022 Sep; 153():113393. PubMed ID: 35834987
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases.
Shen K; Gu Y; Wang Y; Lu Y; Ni Y; Zhong H; Shi Y; Su X
Ther Adv Drug Saf; 2022; 13():20420986221127503. PubMed ID: 36225945
[TBL] [Abstract][Full Text] [Related]
3. Relevance of Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in Routine Clinical Practice: A Pilot Study.
Escudero-Ortiz V; Domínguez-Leñero V; Catalán-Latorre A; Rebollo-Liceaga J; Sureda M
Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745789
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetically guided dosing of oral sorafenib in pediatric hepatocellular carcinoma: A simulation study.
Panetta JC; Campagne O; Gartrell J; Furman W; Stewart CF
Clin Transl Sci; 2021 Nov; 14(6):2152-2160. PubMed ID: 34060723
[TBL] [Abstract][Full Text] [Related]
5. The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma - a substudy of the SORAMIC trial.
Labeur TA; Hofsink Q; Takkenberg RB; van Delden OM; Mathôt RAA; Schinner R; Malfertheiner P; Amthauer H; Schütte K; Basu B; Kuhl C; Mayerle J; Ricke J; Klümpen HJ
Acta Oncol; 2020 Sep; 59(9):1028-1035. PubMed ID: 32366155
[No Abstract] [Full Text] [Related]
6. Therapeutic drug monitoring in cancer--are we missing a trick?
Bardin C; Veal G; Paci A; Chatelut E; Astier A; Levêque D; Widmer N; Beijnen J
Eur J Cancer; 2014 Aug; 50(12):2005-9. PubMed ID: 24878063
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study.
de Wit D; van Erp NP; den Hartigh J; Wolterbeek R; den Hollander-van Deursen M; Labots M; Guchelaar HJ; Verheul HM; Gelderblom H
Ther Drug Monit; 2015 Jun; 37(3):331-8. PubMed ID: 25271729
[TBL] [Abstract][Full Text] [Related]
8. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
Widmer N; Bardin C; Chatelut E; Paci A; Beijnen J; Levêque D; Veal G; Astier A
Eur J Cancer; 2014 Aug; 50(12):2020-36. PubMed ID: 24928190
[TBL] [Abstract][Full Text] [Related]
9. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.
Yu H; Steeghs N; Nijenhuis CM; Schellens JH; Beijnen JH; Huitema AD
Clin Pharmacokinet; 2014 Apr; 53(4):305-25. PubMed ID: 24566736
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study.
Mammatas LH; Zandvliet AS; Rovithi M; Honeywell RJ; Swart EL; Peters GJ; Menke-van der Houven van Oordt CW; Verheul HMW
Cancer Chemother Pharmacol; 2020 May; 85(5):931-940. PubMed ID: 32274565
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities.
Taguchi D; Inoue M; Fukuda K; Yoshida T; Shimazu K; Fujita K; Okuyama H; Matsuhashi N; Tsuji A; Yoshida K; Miura M; Shibata H
Int J Clin Oncol; 2020 Apr; 25(4):531-540. PubMed ID: 31807967
[TBL] [Abstract][Full Text] [Related]
12. Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma.
Hata K; Suetsugu K; Egashira N; Makihara Y; Itoh S; Yoshizumi T; Tanaka M; Kohjima M; Watanabe H; Masuda S; Ieiri I
Cancer Chemother Pharmacol; 2020 Dec; 86(6):803-813. PubMed ID: 33095285
[TBL] [Abstract][Full Text] [Related]
13. The relationship between sunitinib exposure and both efficacy and toxicity in real-world patients with renal cell carcinoma and gastrointestinal stromal tumour.
Westerdijk K; Krens SD; van der Graaf WTA; Mulder SF; van Herpen CML; Smilde T; van Erp NP; Desar IME
Br J Clin Pharmacol; 2021 Feb; 87(2):326-335. PubMed ID: 32358810
[TBL] [Abstract][Full Text] [Related]
14. Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring.
Noda S; Morita SY; Terada T
Biol Pharm Bull; 2022; 45(7):814-823. PubMed ID: 35786588
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study.
Groenland SL; van Eerden RAG; Westerdijk K; Meertens M; Koolen SLW; Moes DJAR; de Vries N; Rosing H; Otten H; Vulink AJE; Desar IME; Imholz ALT; Gelderblom H; van Erp NP; Beijnen JH; Mathijssen RHJ; Huitema ADR; Steeghs N;
Ann Oncol; 2022 Oct; 33(10):1071-1082. PubMed ID: 35777707
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic/Pharmacodynamic Relationship of Enzalutamide and Its Active Metabolite N-Desmethyl Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients.
Joulia ML; Carton E; Jouinot A; Allard M; Huillard O; Khoudour N; Peyromaure M; Zerbib M; Schoemann AT; Vidal M; Goldwasser F; Alexandre J; Blanchet B
Clin Genitourin Cancer; 2020 Apr; 18(2):155-160. PubMed ID: 31630979
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Drug Monitoring of Oral Anticancer Drugs: The Dutch Pharmacology Oncology Group-Therapeutic Drug Monitoring Protocol for a Prospective Study.
Groenland SL; van Eerden RAG; Verheijen RB; Koolen SLW; Moes DJAR; Desar IME; Reyners AKL; Gelderblom HJ; van Erp NP; Mathijssen RHJ; Huitema ADR; Steeghs N
Ther Drug Monit; 2019 Oct; 41(5):561-567. PubMed ID: 31568233
[TBL] [Abstract][Full Text] [Related]
18. Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study.
Cerbone L; Combarel D; Geraud A; Auclin E; Foulon S; Alves Costa Silva C; Colomba E; Carril L; Derosa L; Flippot R; Mir O; Khoudour N; Blanchet B; Escudier B; Paci A; Albiges L
ESMO Open; 2021 Dec; 6(6):100312. PubMed ID: 34864351
[TBL] [Abstract][Full Text] [Related]
19. Axitinib Trough Concentration and its Influence on the Efficacy and Toxicity of Second-line Renal Cell Carcinoma Treatment.
Synowiec Z; Sobańska K; Synowiec T; Teżyk A; Tomczak P; Jabłecka A
Clin Genitourin Cancer; 2022 Aug; 20(4):390.e1-390.e8. PubMed ID: 35428585
[TBL] [Abstract][Full Text] [Related]
20. Association between anlotinib trough plasma concentration and treatment outcomes in advanced non-small-cell lung cancer.
Chen L; Jiang H; Rao JJ; Wang LS; Yan W; Ye J; Lou J
Front Oncol; 2023; 13():1146362. PubMed ID: 36937430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
